Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WTPA intravesical immunotherapy versus pirarubicin after TURBT for prevention of recurrence in non-muscle invasive bladder cancer
ChiCTR-IPR-14005615Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Oct 2014
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of pseudomonas aeruginosa injection in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by First Affiliated Hospital of Shanxi Medical University. Primary endpoint: Recurrence rate. Planned start Oct 2014; status: not yet recruiting.
02
Drugs
pseudomonas aeruginosa injection
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR-IPR-14005615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005615.